Open Day and Free Maths Sessions for Children at Acton Library as Part of Avidator's Social Impact Initiative

"Bring your child along and spark their love for maths. Join us at Acton Library on 14th June!"
Avidator is hosting free Junior Maths Workshops for Key Stage 2 students as part of its Social Impact Initiative. The event takes place on 14th June 2025 at Acton Town Hall Library, offering fun, curriculum-based learning resources including worksheets, quizzes, and tips guides. Seats are limited, and families are encouraged to attend early.
London, UK - 11 June, 2025 - Avidator, an education-focused organisation, is launching Free Junior Maths Workshops for children in Key Stage 2 (Years 3 to 6). This initiative is part of Avidator's wider Social Impact Initiative and will be hosted during a special Open Day on:
Day and Date: Saturday, 14th June 2025
Time: 11:00 AM to 12:00 PM
Location: Acton Town Hall Library, Everyone Active Acton Centre, High Street, Acton, London W3 6NE
About the Workshop
The Junior Maths Workshop is designed to provide free educational support to young learners in the local community. The session includes:
The event is completely free but seating is limited, and parents are encouraged to arrive early to secure a place.
An Initiative to Support Families and Learners
This effort forms part of Avidator's commitment to educational access and inclusion through its CSR programme. The organisation's Social Impact Initiative focuses on:
Providing free, hands-on workshops in public libraries and centres
Supporting students aged 7–11 with learning resources that complement school education
Encouraging community-based learning opportunities across London
Explore More on the Day
Families attending the Open Day can:
Contact & Further Information
Visit: www.avidator.uk
Call: +44 (0) 20 3151 2082
Location: Acton Town Hall Library, High Street, Acton, London W3 6NE
About Avidator
Avidator is a UK-based education platform supporting children, parents, and schools through accessible learning solutions. Its Social Impact Initiative delivers free learning workshops and resources in local communities, aiming to make education engaging and inclusive for all.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CTV News

8 hours ago

• CTV News

Woman off insulin for Type 1 diabetes after a single dose of experimental manufactured stem cells

Amanda Smith celebrates the day, August 1, nearly two years ago, when she stopped taking insulin to manage her type one diabetes, just a few months after getting a dose of experimental stem cells as part of a study. 'I remember, like, being scared and excited, and it's history now,' she said. The 36-year-old nurse and mother is part of a small, but what some call 'milestone study,' of patients with Type 1 Diabetes using manufactured stem cells, designed to grow in the liver and become the full array of islet cells array of pancreatic islet cells that naturally control blood sugar levels. In a study published in the New England Journal of Medicine, researchers report that of the 12 patients who received a single dose of the stem cells, it eliminated the need for insulin in 10 for at least a year and stopped episodes of low blood sugar, or hypoglycemia, which can lead to dangerous complications, even death. For Amanda, the treatment has been a blessing. Diagnosed with late-onset juvenile diabetes when she was 25, she was plagued with sudden bouts of low blood sugar, or hypoglycemia that would leave her faint, despite close monitoring. The risk was a diabetic coma or worse. 'I get emotional because I'm free from those handcuffs ... I don't have that looming over me every day,' she said from her home in London, Ont. 'I took it as a death sentence,' she said. 'I knew, eventually, like the end is always some sort of complication with diabetes,' she said 'We've ... dealt with a lot of patients that have struggled with diabetes. And to be able to see such a transformational change in their life is just amazing,' said Dr. Trevor Reichman, the lead author and the Surgical Director of the Pancreas and Islet Cell Transplant Program at the University Health Network in Toronto. Dr. Trevor Reichman Dr. Trevor Reichman appears for an interview with CTV News. Reichman says it is the first time that scientists have seen this kind of response with implanted stem cell-derived islets. Vertex, a Boston-based biotech company that sponsored the study, derived the cells from embryonic tissue and then found a way to grow them stem cells in large quantities. Researchers, working at centers in the U.S. and at least three transplant hospitals in Canada, infused them into the patient's liver. Over the next four to six months, Reichman said they transformed into the array of hormone-producing cells found in a normal pancreas, and they were monitoring the patients' blood sugar levels in real time. 'In the liver, they're sensing a patient's blood glucose level, and they're secreting the appropriate hormone,' said Reichman. adding that these biological replacements appear to sense changes in 'seconds or milliseconds. Essentially, it's the same as your native islet cells would function.' 'I think the data is just so very exciting, so very, very powerful,' said Dr. Peter Senior, director of the Alberta Diabetes Institute at the University of Alberta. He was not part of this study. 'The primary objective of the study was just to show that the blood sugars were better and that people were not having severe hypoglycemia. They blew past that. Ten of the 12 people are off insulin,' said Senior. ' It's never been done before in history' said Dr. Michael Thompson, director of Vancouver General Diabetes Centre. 'It's first time they a have achieved a high enough levels of insulin in patients,'using a stem cell product 'It's a big advance' he added. But there's a tradeoff. The patients, however, require immune-suppressing drugs for life, so that the immune system doesn't destroy the cells. There are risks to these immunosuppressive medications, including a higher risk of some cancers, infections, and high blood pressure. Amanda says it is nothing like her constant terror that she might slip into a sudden diabetic coma. 'Taking a couple of pills three times a day is nothing. I take it with breakfast, lunch, and dinner. It's easy. No comparison, none,' she said. 'And I know it's a huge relief for my family, especially my husband, that's for sure.' The study also reports that two patients in the study died, one likely as a result of complications from that immunosuppression, which Dr. Reichman says underscores the need for patients to be closely monitored at experienced transplant centers. A second patient, according to the study, died of severe dementia. Off-the-shelf live cell therapy The idea of using cells implanted in the body to produce insulin, instead of insulin injections, began in Canada 25 years ago. Researchers in Alberta pioneered the Edmonton Protocol. It uses insulin-producing islet cells removed from diseased organ donors that are implanted into those with hard-to-manage Type 1 Diabetes. Some 2,500 patients have been treated around the world, according to the University of Alberta, which reports 80 per cent were able to stop taking insulin injections for a median time of 95 days. Stem cells pipettes (Image credit: Vertex) But the number of procedures is limited because there aren't enough organ donors to meet the demand, and patients also require long-term immune suppression. So, there have been some two dozen companies around the world looking at other ways of getting manufactured islet cells to regulate blood sugar as a replacement for insulin. The Vertex cells, originally called VX-880, have been renamed Zimislecel. The Boston-based pharmaceutical company (says it is ramping up production, as it 'These are fresh, brand-new cells – they're not 60-year-old cells that have already had a life, and we're repurposing them,' said Senior, who works in Edmonton. It pushes the boundary of therapy forward because there is the potential to create a renewable source of insulin-producing cells instead of waiting for cells from deceased donors,' he added. 'I think we've got a treatment for diabetes where we are no longer constrained by organ donors,' said Senior. 'We've got potentially a limitless source of cells that could be used, and that is a massively huge step forward in terms of a cell therapy becoming a reality.' The next step is for someone to produce stem cells that don't require immune suppression, by either genetically engineering the cells or encapsulating them to make them invisible to immune attack. Several pilot studies are underway. It's a welcome advance, according to Senior. While insulin therapy has been a lifesaver for many since its discovery in Toronto by Banting and Best in 1921, it's never been a cure. Stem Cells (Image credit: Vertex) 'I think people with diabetes deserve some of the transformative treatments we've seen in cancer and other diseases but we've been stuck essentially doing the same thing for 100 years,' said Senior. In Canada, there are some 300000 people with Type 1 diabetes. Thirty-two new cases are diagnosed each day. The number of new cases per year increased by 34 per cent between 2000 and 2022, according to Breakthrough TD1(formerly the Juvenile Diabetes Foundation of Canada). Unlike Type 2 diabetes, which is linked to environmental, dietary, and genetic factors, the exact cause of Type 1 diabetes is still unknown, but doctors say the immune system mistakenly attacks insulin-producing islet cells in the pancreas, resulting in a gradual decline in the availability of insulin to regulate blood sugar. Questions remain The study is being continued to include a total of 50 patients, in Vancouver, Edmonton, Toronto and the U.S., with Dr. Reichman's team actively recruiting candidates. There are still many questions. Dr. Reichman admits that no one knows how long these implanted cells will last. Amanda hasn't required any insulin inections for almost two years, the longest documented period so far. He adds there are no signs that the other nine, who also went off insulin, have gone back on the injections since their stem cell infusion. Unclear also is whether this therapy will reduce the longer-term and burdensome complications of diabetes, including heart problems, amputations, kidney failure, and vision loss. However, data from patients treated with the Edmonton protocol, using tissue from deceased donors, show signs of reduced complications, a promising sign for the newer therapy, according to Dr. Thompson. The other concern is that not all patients with severe hypoglycemia may want to make the same choice as Amanda, swapping the diabetes risks for those that come with the anti-rejection medications. 'Taking a couple of pills three times a day is nothing. It's easy. There's no comparison, none,' she said. Another question is that a single treatment therapy for this disease could come with a very high price tag. 'We'll have to wait and see,' said Reichman. Amanda Smith, meanwhile, tries to enjoy her freedom with her family and her work at a long-term care home, without thinking too far ahead. 'What happens if the cells stop working or something? You know, I just try and live right now, and I feel so blessed.' She debates the question - does she have diabetes anymore? 'I don't take any insulin anymore. I don't take medication for diabetes anymore. So, I feel like a regular person again without diabetes.'

National Post

9 hours ago

• National Post

What we know about yawning, from why we do it to why it's contagious

Yawning is strange. Article content It's not obviously just mechanical, like a burp to release gas pressure, or just psychological, like a yelp to express fear or excitement. A yawn is more like a sneeze or a hiccup, an involuntary breath event that is sometimes more or less resistible. Article content Article content But what is really strange, almost unique among human behaviours, is that yawning is contagious. Article content New research on chimpanzees by a British team of cognitive scientists shows contagious yawning is not only common in other species, and can happen between species, but that it can also be induced in chimps by an obviously artificial humanoid robot, an android 'agent' that is just a creepy looking disembodied head and shoulders, and which doesn't even breathe, but which can still give a believable facsimile of a yawn. Article content Article content The paper, published this month in Nature Scientific Reports, details an experiment in which the chimps were shown three behaviours by the android: a full wide-mouth yawn, a more moderate gaping mouth, and a closed mouth. Article content 'The results showed that adult chimpanzees exhibited across-agent yawn contagion, with a graded response: the highest contagion occurred when the android displayed a fully wide-open mouth (Yawn condition), a reduced response when the mouth was partially opened (Gape condition), and no contagion when the android's mouth was closed,' the paper says. Article content Article content And the chimps did not only yawn in response to the yawning robot. They also 'engaged in behaviours associated with drowsiness,' basically by preparing a comfortable place to lie down. Article content Article content 'This suggests that yawning by an unfamiliar model may act as a contextual cue for rest, rather than merely triggering a motor resonance response,' the paper says. Article content Diverse species exhibit contagious yawning, certainly mammals like dogs and cats, but even fish, whose respiratory system shares evolutionary origins with our own. Article content Most vertebrates yawn, but those that are known to yawn contagiously are usually pack animals, somehow social. This suggests the evolutionary purpose of the yawn is at least partly at the level of the group, not just the individual. A sneeze just tries to blast stuff out of your nose, a burp just lets gas out of your belly, but a yawn means something to other people. Article content Not always, of course, Yawning might, for example, help cool the brain for optimal performance, as one theory holds. But yawning also involves empathy, as its contagious aspect shows. It is a social phenomenon, and catching, like laughter. Article content 'What I find strange is that if we see someone walking, we don't an feel urge to walk. But with yawning, we do,' said Ramiro Joly-Mascheroni, a research fellow in social and cognitive neuroscience at City St. George's University of London in the U.K., in an interview.

Globe and Mail

2 days ago

• Globe and Mail

Is Increased Focus on Hypersonic Tech Opening New Doors for Rocket Lab?

In recent years, the rapid development and adoption of hypersonic technology across industries, from aerospace and defense to space exploration, have opened new growth avenues for Rocket Lab USA RKLB, a key player in hypersonic testing with its HASTE launch system. With commercial firms and government agencies ramping up investments in advanced hypersonic systems to bolster space access and national security, RKLB remains well-positioned to capitalize on this accelerating technological shift. Notably, Rocket Lab's HAEST (Hypersonic accelerator suborbital test electron) is a suborbital testbed launch vehicle that provides reliable, high-cadence flight test opportunities needed to boost hypersonic and suborbital system technology development. In April 2025, Rocket Lab secured a contract from Kratos Defense to conduct a full-scale hypersonic test flight for the U.S. Department of Defense. Additionally, RKLB's HASTE platform has been included in two major defense frameworks — the $46 billion Enterprise-Wide Agile Acquisition Contract with the U.S. Air Force and the UK Ministry of Defence's £1 billion ($1.3 billion) Hypersonic Technologies & Capability Development Framework. These programs allow Rocket Lab to compete for launch and engineering services in advancing hypersonic technologies. The inclusion across both U.S. and UK initiatives underscores the growing demand for HASTE in defense testing and is likely to significantly boost Rocket Lab's future revenue stream. While HASTE has not yet won any purely commercial contract, its demonstrated reliability and cadence in the defense sector may soon open doors to non-defense payload opportunities. Other Stocks Focusing on Hypersonic As increased investment in hypersonic technology has become a global trend lately, with nations like the United States, the United Kingdom, and China significantly boosting funding for research and development in this tech, other stocks like Lockheed Martin LMT and RTX Corp. RTX are also indulging in advanced hypersonic technology developments. Notably, Lockheed Martin has been developing highly advanced hypersonic technology for the past 60 years. To this end, the company is currently working in partnership with DARPA, the U.S. Air Force, the U.S. Army, and the U.S. Navy to transition hypersonic concepts to operational reality. LMT's Conventional Prompt Strike is a hypersonic boost-glide missile currently under development, which boasts the capability to provide longer range, shorter flight times, and high survivability against enemy defenses. On the other hand, RTX is working across its business and domains to move advanced hypersonic capabilities from creation to testing and into the hands of warfighters at top speed. RTX is currently involved in the design of the Hypersonic Attack Cruise Missile, which leverages Northrop Grumman's scramjet propulsion to travel at more than five times the speed of sound and cover vast distances in minutes. The U.S. Air Force currently expects this missile to be operational by fiscal 2027. The Zacks Rundown for RKLB Shares of RKLB have surged 467.2% in the past year compared with the industry 's 40.9% growth. The company's shares are trading at a premium on a relative basis, with its forward 12-month Price/Sales being 17.85X compared with its industry's average of 9.65X. The Zacks Consensus Estimate for RKLB's 2025 and 2026 earnings has improved over the past 60 days. RKLB currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lockheed Martin Corporation (LMT): Free Stock Analysis Report Rocket Lab Corporation (RKLB): Free Stock Analysis Report